Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
The players and management of Mumbai City FC presented patients with exclusive gifts, symbolizing support and appreciation for their fight against cancer
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company has been issued ‘Form 483’ with two observations
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Subscribe To Our Newsletter & Stay Updated
